6-MeO-isoDMT, or 6-OMe-isoDMT, also known as 6-methoxy-N,N-dimethylisotryptamine, is a serotonin 5-HT2A receptor agonist, putative serotonergic psychedelic, and psychoplastogen of the isotryptamine group. It is the isotryptamine analogue of the psychedelic 5-MeO-DMT and is a positional isomer of the non-hallucinogenic psychoplastogen 5-MeO-isoDMT.
The drug has been found to substitute for DOM and hence to produce hallucinogen-like effects in animal drug discrimination tests. However, it has greatly reduced hallucinogenic potential in terms of the head-twitch response, a behavioral proxy of psychedelic effects, compared to 5-MeO-DMT. It has even been described as "non-hallucinogenic" in at least one publication, although this does not strictly seem to be true. Conversely, 6-MeO-isoDMT has comparable psychoplastogenic potency and effects compared to 5-MeO-DMT. These effects are blocked by the serotonin 5-HT2A receptor antagonist ketanserin. Certain analogues of 6-MeO-isoDMT, like isoDMT, 5-MeO-isoDMT, and zalsupindole (DLX-001; AAZ-A-154; (R)-5-MeO-α-methyl-isoDMT), produce no head-twitch response at all and hence appear to be fully non-hallucinogenic, similarly to 6-MeO-DMT (the tryptamine analogue of 5-MeO-isoDMT). However, like 6-MeO-isoDMT, they retain potent psychoplastogenic effects.
6-MeO-isoDMT was first described in the scientific literature by 1984. It was subsequently further characterized in 2020. Confusingly, the drug has been referred to as "5-MeO-isoDMT" (or rather "5-OMe-isoDMT") in some publications.
See also
- 2-Bromo-LSD
- Ariadne (drug)
- ITI-1549
- Lisuride
- Tabernanthalog
References
